HCPLive Network

H. pylori Status May Affect Recurrent Ulcer Bleeding in Aspirin Users

THURSDAY, March 28 (HealthDay News) -- Risk of recurrent ulcer bleeding is low in long-term low-dose aspirin (ASA) users with a history of ulcer bleeding and eradication of Helicobacter pylori (H. pylori), but high in ASA users with a history of ulcer bleeding and negative for H. pylori, according to research published in the March issue of Gastroenterology.

Francis K.L. Chan, MD, of the Chinese University of Hong Kong, and colleagues conducted a prospective study to compare the incidence of recurrent ulcer bleeding in three different cohorts of patients: ASA users with a history of ulcer and eradication of H. pylori, ASA users with a history of ulcer and negative for H. pylori, and new ASA users with no history of ulcer and unknown H. pylori status.

According to the researchers, the incidence rate of ulcer bleeding in the H. pylori-eradicated cohort was similar to that found in the new ASA users cohort (0.97 per 100 patient-years [95 percent confidence interval, 0.53 to 1.80] and 0.66, respectively). In contrast, the H. pylori-negative cohort had the highest incidence of recurrent bleeding (5.22). The incidence of ulcer bleeding was five times higher than that found in the H. pylori-eradicated cohort and eight times higher than that found in the new ASA users cohort.

"ASA users who developed ulcer bleeding without current or past H. pylori infection are at high risk of recurrent bleeding," the authors write. "Our study provides novel data to guideline committees to refine their treatment recommendations for ASA users who are at risk of ulcer bleeding."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Commoditycare is coming. To distinguish yourself, you will need to innovate and avoid the traps driving your competitors. Patients and payers will be watching you and voting with their wallets.
A drug to treat acquired hemophilia A was approved by the FDA, according to a statement made by manufacturer Baxter International Inc.
The FDA has approved Rixubis for the treatment of hemophilia B in children, manufacturer Baxter International Inc. announced.
More Reading